skip to Main Content

Treatment Action Group Statement on Early Findings from HPTN 084

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.
Read more

ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis

The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017
Read more

Two Out of Three Ain’t Bad

In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).
Read more
Back To Top